Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07027514 · ClinicalTrials.gov registry record · Phase 1

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Ankyra Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
5
Study locations

NCT07027514 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Ankyra Therapeutics. The registered enrollment target is 60 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07027514, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Ankyra Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG tolododekin alfa
  • DRUG Cetrelimab

Study Locations (5)

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • Icahn School of Medicine at Mount Sinai - New York

Indiana

  • Community Health Network - Indianapolis

Michigan

  • Barbara Ann Karmanos Cancer Hospital - Detroit

North Carolina

  • FirstHealth of the Carolinas - Pinehurst

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-22
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Ankyra Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07027514

The ClinicalTrials.gov registry entry for NCT07027514 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Ankyra Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which tolododekin alfa is the first listed.

NCT07027514 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Indiana, Michigan.

Frequently Asked Questions

What is clinical trial NCT07027514 about?

NCT07027514 is a clinical study titled "A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer". A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who ha...

What is the current status of trial NCT07027514?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-22. Estimated completion is 2028-12-31.

What conditions does trial NCT07027514 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT07027514?

The interventions under investigation include: tolododekin alfa (DRUG), Cetrelimab (DRUG).

Who is sponsoring clinical trial NCT07027514?

This trial is sponsored by Ankyra Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07027514 being conducted?

This trial has 5 study locations across Indiana, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.